

PUMA BIOTECHNOLOGY, INC.  
Form 8-K  
June 11, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 9, 2015**

**PUMA BIOTECHNOLOGY, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-35703**  
**(Commission**

**File Number)**  
**10880 Wilshire Boulevard, Suite 2150**

**77-0683487**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form 8-K

**Los Angeles, California 90024**

**(Address of principal executive offices) (Zip Code)**

**(424) 248-6500**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 9, 2015, at the 2015 Annual Meeting of Stockholders (the "2015 Annual Meeting") of Puma Biotechnology, Inc., a Delaware corporation (the "Company"), the Company's stockholders approved an amendment (the "Amendment") to the Company's 2011 Incentive Award Plan (the "Plan"), increasing the number of shares of common stock the Company is authorized to issue under the Plan by 4,000,000 shares, from 6,529,412 shares to 10,529,412 shares. A copy of the Amendment was attached as Appendix A to the definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2015, the terms and conditions of which are incorporated herein by reference.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

(a) The 2015 Annual Meeting was held at 1:00 p.m. Pacific Daylight Time on June 9, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

(b) At the 2015 Annual Meeting, the stockholders of the Company:

**Proposal 1:** Elected the four nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company's next annual meeting of stockholders in 2016, or until a successor has been duly elected and qualified or until their earlier resignation or removal.

Nominee	For	Withheld	Broker Non-Votes
Alan H. Auerbach	29,081,526	342,928	646,324
Thomas R. Malley	27,398,251	2,026,203	646,324
Jay M. Moyes	25,863,576	3,560,878	646,324
Troy E. Wilson	29,299,288	125,166	646,324

**Proposal 2:** Approved, on an advisory basis, the compensation of the Company's named executive officers.

For	Against	Abstain	Broker Non-Votes
26,892,661	2,506,460	25,333	646,324

**Proposal 3:** Ratified the selection of PKF Certified Public Accountants, a Professional Corporation, as the Company's independent registered accounting firm for the fiscal year ending December 31, 2015.

For	Against	Abstain	Broker Non-Votes
30,045,856	5,946	18,976	0

**Proposal 4:** Approved the Amendment to the Plan referred to in Item 5.02 above.

			<b>Broker</b>
	<b>For</b>	<b>Against</b>	<b>Abstain</b>
	21,523,467	7,890,474	10,513
			<b>Non-Votes</b>
			646,324

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PUMA BIOTECHNOLOGY, INC.

Date: June 11, 2015

By: /s/ Alan H. Auerbach  
Alan H. Auerbach  
President and Chief Executive Officer